Related references
Note: Only part of the references are listed.Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid
John E. Eaton et al.
HEPATOLOGY (2020)
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
Carla F. Murillo Perez et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis
Minami Yagi et al.
LIVER INTERNATIONAL (2020)
Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis
Akira Honda et al.
HEPATOLOGY (2019)
4 Emerging novel treatments for autoimmune liver diseases
Atsushi Tanaka
HEPATOLOGY RESEARCH (2019)
Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan
Atsushi Tanaka et al.
HEPATOLOGY RESEARCH (2019)
Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature
Christopher L. Bowlus et al.
JOURNAL OF AUTOIMMUNITY (2019)
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
Maren H. Harms et al.
JOURNAL OF HEPATOLOGY (2019)
Clinical Trials in PBC Going Forward
Christophe Corpechot
SEMINARS IN LIVER DISEASE (2019)
Additional fibrate treatment in UDCA-refractory PBC patients
Sung Won Chung et al.
LIVER INTERNATIONAL (2019)
Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response
Christophe Corpechot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database
Marco Marzioni et al.
DIGESTIVE AND LIVER DISEASE (2019)
New treatments/targets for primary biliary cholangitis
Christophe Corpechot et al.
JHEP REPORTS (2019)
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C. Corpechot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Marco Carbone et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
NI-0801, an Anti-Chemokine (C-X-C Motif) Ligand 10 Antibody, in Patients With Primary Biliary Cholangitis and an Incomplete Response to Ursodeoxycholic Acid
Kathy L. de Graaf et al.
HEPATOLOGY COMMUNICATIONS (2018)
Finding the cure for primary biliary cholangitis - Still waiting
Atsushi Tanaka et al.
LIVER INTERNATIONAL (2017)
Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
A. C. Cheung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Ustekinumab for Patients With Primary Biliary Cholangitis Who Have an Inadequate Response to Ursodeoxycholic Acid: A Proof-of-Concept Study
Gideon M. Hirschfield et al.
HEPATOLOGY (2016)
A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia
Kenichi Hosonuma et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy
Willem J. Lammers et al.
GASTROENTEROLOGY (2015)
Novel therapeutic targets in primary biliary cirrhosis
Jessica K. Dyson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid
Akira Honda et al.
HEPATOLOGY (2013)
Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
Teru Kumagi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M. M. Kuiper et al.
GASTROENTEROLOGY (2009)
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Christophe Corpechot et al.
HEPATOLOGY (2008)
The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study
Shinji Iwasaki et al.
HEPATOLOGY RESEARCH (2008)
Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials
Jian Shi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés et al.
GASTROENTEROLOGY (2006)
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis
J Itakura et al.
HEPATOLOGY RESEARCH (2004)
Share Paper
